Hypervirulent Acinetobacter baumannii (hvAB): The Convergence of Virulence and Multidrug Resistance

TL;DR

This paper reviews the rise of hypervirulent Acinetobacter baumannii, which combines high virulence with drug resistance, creating major challenges in healthcare.

Contribution

The paper provides a comprehensive review of the molecular mechanisms and clinical impact of hypervirulent A. baumannii strains.

Findings

Hypervirulent A. baumannii strains exhibit both high virulence and multidrug resistance.

These strains are causing significant challenges in clinical management and infection control.

The paper highlights the global spread and evolving nature of hvAB.

Abstract

Acinetobacter baumannii has become a formidable pathogen in healthcare systems worldwide, primarily due to its remarkable capacity to develop multidrug resistance and cause life-threatening infections. While traditionally A. baumannii is considered an opportunistic pathogen of low virulence, accumulating evidence now underscores the emergence of hypervirulent A. baumannii (hvAB) strains. These strains combine heightened pathogenicity with extensive drug resistance, posing unprecedented challenges for clinical management and infection containment. This review comprehensively explores the molecular mechanisms driving hvAB’s virulence and antimicrobial resistance and its evolutionary trajectory, clinical presentations, and global epidemiology. Additionally, we evaluate potential therapeutic strategies and their broader public health implications.